(Q57487974)

1

0 references

Karin Fattinger

3

0 references

Hans R. Brunner

4

0 references

J??r??me Biollaz

5

0 references

Thierry Buclin

2

0 references

Hans R Brunner

4

0 references

Jérôme Biollaz

Clinical Pharmacokinetics

5

0 references

language of work or name

English

0 references

publication date

2002

0 references

published in

0 references

volume

41

0 references

issue

2

0 references

page(s)

137-152

0 references

137-52

0 references

exact match

https://scigraph.springernature.com/pub.10.2165/00003088-200241020-00005

0 references

cites work

Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.

1 reference

12 December 2020

Effects of Losartan on a Background of Hydrochlorothiazide in Patients With Hypertension

1 reference

12 December 2020

Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group

1 reference

12 December 2020

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

1 reference

12 December 2020

Angiotensin II receptor antagonists

1 reference

12 December 2020

Continuous, real-time, noninvasive monitor of blood pressure: Penaz methodology applied to the finger.

1 reference

12 December 2020

Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics

1 reference

12 December 2020

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome

1 reference

12 December 2020

The importance of modeling interoccasion variability in population pharmacokinetic analyses

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers

1 reference

12 December 2020

Comparison of the oral angiotensin II receptor antagonist UP 269-6 or enalapril 20 mg on blood pressure and neurohormonal effects in salt-deplete man

1 reference

12 December 2020

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine

1 reference

12 December 2020

Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension

1 reference

12 December 2020

Calculation of trough:peak ratio of antihypertensive treatment from ambulatory blood pressure: methodological aspects

1 reference

12 December 2020

Concepts and usefulness of pharmacokinetic-pharmacodynamic modelling.

1 reference

12 December 2020

Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4- yl]methyl]-1H-benzimidazole-7-carboxylic acid (CV-11974), and its prodrug, (+/-)-1-(cyclohexyloxycarbonyloxy

1 reference

12 December 2020

Clinical and hormonal effects of the new angiotensin II receptor antagonist LRB081

1 reference

12 December 2020

Losartan with hydrochlorothiazide in the treatment of hypertension.

1 reference

12 December 2020

Comparison of the angiotensin II antagonist UP269-6 with the angiotensin converting enzyme inhibitor enalapril in normotensive volunteers challenged with angiotensin I

1 reference

12 December 2020

Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension.

1 reference

12 December 2020

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

12 December 2020

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

12 December 2020

Dose-response relationships following oral administration of DuP 753 to normal humans

1 reference

12 December 2020

Evaluation of noninvasive blood pressure recording by photoplethysmography in clinical studies using angiotensin challenges

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors

1 reference

12 December 2020

Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers.

1 reference

12 December 2020

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

12 December 2020

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

1 reference

12 December 2020

Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists

1 reference

12 December 2020

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model

1 reference

12 December 2020

Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients

1 reference

12 December 2020

Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system

1 reference

12 December 2020

SC-52458, an Orally Active Angiotensin II-Receptor Antagonist: Inhibition of Blood Pressure Response to Angiotensin II Challenges and Pharmacokinetics in Normal Volunteers

1 reference

12 December 2020

Angiotensin II antagonism and plasma radioreceptor-kinetics of candesartan in man

1 reference

12 December 2020

Intestinal peptide transport systems and oral drug availability

1 reference

12 December 2020

Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.

1 reference

12 December 2020

Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.

1 reference

12 December 2020

Characterization of the angiotensin II receptor antagonist TCV-116 in healthy volunteers

1 reference

12 December 2020

Non-invasive vs. invasive beat-to-beat monitoring of blood pressure

1 reference

12 December 2020

Learning versus confirming in clinical drug development

1 reference

12 December 2020